- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03629665
Combining Language Therapy With rTMS in Aphasia (ILAT+rTMS)
Combining Language Therapy With rTMS in Chronic Stage of Aphasia: A Randomized Controlled Trial
Study Overview
Status
Conditions
Detailed Description
New neuromodulation technologies, such as transcranial magnetic stimulation (TMS), are promising tools for neurorehabilitation, aphasia therapy included. Combined with behavioral techniques, Intensive Language-Action Therapy (ILAT), TMS could substantially amplify the beneficial effect of such behavioral therapy alone.
In this randomized study of 17 subjects with post-stroke aphasia in the chronic stage will be studied the combined effect of ILAT and 1-Hz placebo-controlled navigated repetitive TMS (rTMS) to the right-hemispheric inferior frontal cortex (pars triangularis). Participant will be randomized to groups A and B. Participants in group A will receive a 2-week period of rTMS during naming training where they name pictures every ten second displayed on the screen, followed by 2-weeks of rTMS and naming combined with ILAT. Those in group B will receive the same behavioral therapy but TMS is replaced by sham stimulation.
Language performance will be measured before, during and after the interventions for 3 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age between 18 and 75 years
- presence of a single clinically documented stroke
- chronic stage (at least 12 months post-stroke)
- aphasia documented using the WAB test
- no recurring utterances or severe global (total) aphasia
- residual ability to understand simple task instructions
- availability of information about medication
- right-handedness
- native speakers of Finnish.
Exclusion Criteria:
- severe global (total) aphasia (Boston naming test less 3 points)
- neglect, agnosia, severe vision impairment or hearing loss
- severe attention or memory deficits
- left-handedness
- cardiac pacemaker or other stimulators
- diagnosis of severe diabetes or severe depression
- additional neurological diagnoses
- other interventions, including speech therapy, in the same time period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: rTMS and naming combined with ILAT
Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
|
ILAT includes communicative language games played in an interactive small-group setting.
Three persons with aphasia and one therapist sit around a table and have picture cards in front of them.
The card sets include two items of each object or action picture.
All participants take turns in making verbal requests.
There will be 5 daily sessions (3 hours per session) for two weeks.
Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training.
The primary targeted area is the right pars triangularis.
In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
|
Sham Comparator: sham rTMS and naming combined with ILAT
Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
|
ILAT includes communicative language games played in an interactive small-group setting.
Three persons with aphasia and one therapist sit around a table and have picture cards in front of them.
The card sets include two items of each object or action picture.
All participants take turns in making verbal requests.
There will be 5 daily sessions (3 hours per session) for two weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Western Aphasia Battery
Time Frame: Change in AQ performed at weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
aphasia quotient (AQ) measurement
|
Change in AQ performed at weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Boston naming test
Time Frame: Change in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
picture naming ability
|
Change in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
The Action naming test
Time Frame: Change in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
picture naming ability
|
Change in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anu Klippi, Professor, University of Helsinki
- Study Chair: Jyrki Mäkelä, MD, BioMag Laboratory, Helsinki University Hospital
- Study Chair: Friedemann Pulvermüller, Professor, Brain Language Laboratory, Department of Philosophy and Humanities, WE4, Freie Universität Berlin
- Study Chair: Risto Ilmoniemi, Professor, Department of Neuroscience and Biomedical Engineering, Aalto University School of Science
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HelsinkiUniversity/Logopedics
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aphasia
-
University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Aphasia | Stroke, Ischemic | Aphasia, Broca | Aphasia, Anomic | Aphasia, Global | Aphasia, Fluent | Aphasia, Mixed | Aphasia, Jargon | Aphasia, Expressive | Aphasia, ConductionUnited States
-
University of Texas at AustinUniversity of California, San Francisco; National Institute on Deafness and...Active, not recruitingPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, ProgressiveUnited States
-
Institute for Bioengineering of CataloniaHospital Universitari Joan XXIII de Tarragona.; Universitat Pompeu FabraCompletedAphasia | Aphasia, Broca | Aphasia, Wernicke | Aphasia, Fluent | Aphasia, NonfluentSpain
-
Flint Rehabilitation Devices, LLCUniversity of TexasCompleted
-
Mayo ClinicNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingPrimary Progressive Aphasia | Apraxia of Speech | PPA | Non-fluent Aphasia | Primary Progressive Non-fluent AphasiaUnited States
-
University of California, BerkeleyUniversity of California, San Francisco; California State University, East Bay and other collaboratorsRecruitingAphasia | Aphasia, Acquired | Aphasia Non Fluent | Aphasia, FluentUnited States
-
Mayo ClinicCompletedPrimary Progressive Aphasia | Aphasia | Semantic Dementia | Apraxia of Speech | Primary Progressive Nonfluent Aphasia | PPA | Non-fluent Aphasia | Progressive AphasiaUnited States
-
Montreal Heart InstituteActive, not recruitingNeurodegenerative Diseases | Primary Progressive Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Non-fluent AphasiaCanada
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States, Canada
-
University of British ColumbiaTerminatedPrimary Progressive Nonfluent AphasiaCanada
Clinical Trials on Intensive Language-Action Therapy (ILAT)
-
University of Massachusetts, AmherstNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchUnknownPost-Stroke Chronic Aphasia | Anomia (Word-retrieval Impairment)Germany
-
Charité Neurocure AG FlöelUnknownAphasia | Anomia (Word-Finding Impairment)Germany
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia | Logopenic Progressive Aphasia | Non-Fluent Primary Progressive AphasiaUnited States, Canada
-
Assiut UniversityCompleted
-
University College, LondonCompletedLanguage Difficulties in British Sign Language
-
Johns Hopkins UniversityActive, not recruitingPrimary Progressive AphasiaUnited States
-
Samsung Medical CenterCompletedStroke | Rehabilitation | LanguageKorea, Republic of
-
Johns Hopkins UniversityNational Institutes of Health (NIH); National Institute on Deafness and Other...RecruitingPrimary Progressive Aphasia | MCI | FTDUnited States